Johnson & Johnson (JNJ) therapy nipocalimab granted US FDA Fast Track designation in systemic lupus erythematosus (SLE)
Importance
Level 1
#JOHNSON & JOHNSON#JNJ.US#FDA#EQUITIES#EU SESSION#US SESSION#PHARMACEUTICALS#PHARMACEUTICALS (GROUP)#PHARMACEUTICALS, BIOTECHNOLOGY & LIFE SCIENCES#S&P 500 INDEX#JNJ#US EQUITIES